• HITIQ wins deal with German Ice Hockey Federation to trial its smart mouthguard technology.
  • Neuren gets third IND approval from US FDA

HITIQ lands trial deal with German ice hockey

Aussie medtech HITIQ (ASX:HIQ) has entered into a trial agreement with the German Ice Hockey Federation (DEB) for its smart mouthguard technology.

The smart mouthguard will be deployed into the Men’s National and U18s Programs, and will be used in the upcoming IIHF Men’s World Championships.

The German DEB aims to increase visibility and importance on head impact surveillance, becoming the first professional ice hockey body to investigate this innovative technology.

Ice hockey is a lucrative sports market with more than 40 ranked countries within the International Ice Hockey Federation (IIHF).

The latest deal expands HITIQ’s coverage in elite sports markets, with its mouthguard already being trialled or used in US college football and Australia’s AFL and AFLW, NRL and rugby union.

“HITIQ continues to strategically build a global user footprint with the deployment of technology into an exciting new market in ice hockey,” said CEO, Mike Vegar.

“We look forward to working with the progressive key stakeholders in DEB, to deliver key data and improve their care model across their junior and senior programs.”


HITIQ share price today:


Neuren gets third FDA green light for NNZ-2591

Neuren has received approval from the US FDA to proceed with the Phase 2 trial of NNZ-2591 in Pitt Hopkins syndrome (PTHS).

The Phase 2 trial will be conducted at four hospitals in the US, enrolling up to 20 children aged 3 to 17 years with PTHS, over 13 weeks of treatment with NNZ-2591.

PTHS is a neuro-developmental condition affecting both males and females, caused by the loss of one copy or a mutation of the TCF4 gene on chromosome 18.

It’s estimated that between 1 in 34,000 and 1 in 41,000 people suffer from the condition, which is usually characterised by lack of speech, seizures, and distinctive facial features.

Some individuals with PTHS are also diagnosed with autism.

Neuren now has three INDs (Investigational New Drug) approvals for NNZ-2591 that are active. The other two approvals are for Phelan-McDermid syndrome (PMS) and Angelman syndrome (AS).


Neuren share price today: